ReviewGynecologic oncology2016
Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
Review in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A retrospective case-control study of in vitro fertilization in patients with BRCA1/2 mutation.Journal of assisted reproduction and genetics · 2026Article
- Article
- Assessment of knowledge and awareness about ovarian cancer and its risk factors among women in Jazan, Saudi Arabia: a cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China.Scientific reports · 2024Article
- Genetic Testing for Cancer Risk and Perceived Importance of Genetic Information Among US Population by Race and Ethnicity: a Cross-sectional Study.Journal of racial and ethnic health disparities · 2024Article
- Article
- Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.Journal of ovarian research · 2023Article
- Article
- Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.Hereditary cancer in clinical practice · 2022Article
- Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes.Frontiers in oncology · 2022Article
- Healthcare professionals' responsibility for informing relatives at risk of hereditary disease.Journal of medical ethics · 2020Article
- Article
- Article
- Family history of cancer and DNA damage response genes: Two sides of the same coin?Thoracic cancer · 2019Article
- Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.Frontiers in oncology · 2019Article
- Inherited Cancer in the Age of Next-Generation Sequencing.Biological research for nursing · 2018Review
- Predictors of next-generation sequencing panel selection using a shared decision-making approach.NPJ genomic medicine · 2018Article
- Improving attendance to genetic counselling services for gynaecological oncology patients.Gynecologic oncology research and practice · 2018Article
- Case Report of Menopausal Woman Diagnosed with Endometrial Cancer after Colon Cancer with Germline Mutation inJournal of menopausal medicine · 2017Article
- Implementing Precision Medicine: The Ethical Challenges.Trends in pharmacological sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Obstetrician/gynecologists and gynecologic oncologists serve an integral role in the care of women at increased hereditary risk of cancer. Their contribution includes initial identification of high risk patients, screening procedures like bimanual exam, trans-vaginal ultrasound and endometrial biopsy, prophylaxis via TAH and/or BSO, and chemoprevention. Further, gynecologists also serve a central role in the management of the secondary repercussions of efforts to mitigate increased cancer risks, including vasomotor symptoms, sexual function, bone health, cardiovascular disease, and mental health. The past several years has seen multiple new high and moderate penetrance genes introduced into the clinical care of women at increased risk of gynecologic malignancy. Awareness of these new genes and the availability of new multi-gene panel tests is critical for providers on the front-line of women's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.